Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening.
Chemotherapeutic drug delivery can be enhanced by administering drugs into the internal carotid or vertebral artery circulation after osmotic opening of the blood-brain barrier (BBB). As evidence of the clinical implications of this technique, radiographic documentation of central nervous system (CNS) tumor regression was observed in three patients concurrent with the development of new tumor nodule(s) in portions of the brain distant from the region of osmotic blood-brain barrier opening. These three patients, one with metastatic carcinoma of the breast, one with glioblastoma, and one with primary CNS lymphoma, highlight the importance of drug delivery to CNS malignancies.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000556:secondary; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008353:Mannitol / Q000627:therapeutic use*; D008727:Methotrexate / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed; D014882:Water-Electrolyte Balance / Q000187:drug effects*
D011344:Procarbazine; D008353:Mannitol; D003520:Cyclophosphamide; D002955:Leucovorin; D008727:Methotrexate